Cardiovascular safety and pharmacokinetics of almotriptan:: a randomized, double-blind, placebo-controlled, crossover clinical trial in healthy volunteers

被引：0
|
作者：
Salvà, M [1 ]
Jansat, JM [1 ]
Martínez-Tobed, A [1 ]
机构：
[1] Almiral Prodesfarma SA, Barcelona, Spain
来源：
CEPHALALGIA | 2003年 / 23卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：706 / 706
页数：1
相关论文
共 50 条
  • [21] Safety and tolerability of Ganoderma lucidum in healthy subjects:: A double-blind randomized placebo-controlled trial
    Wicks, Sheila M.
    Tong, Robin
    Wang, Chong-Zhi
    O'Connor, Michael
    Karrison, Theodore
    Li, Shang
    Moss, Jonathan
    Yuan, Chun-Su
    [J]. AMERICAN JOURNAL OF CHINESE MEDICINE, 2007, 35 (03): : 407 - 414
  • [22] A Phase I, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Tolerance of Oil Palm Phenolics (OPP) in Healthy Volunteers
    Tadj, Nur Balqis Muhammad Ismail
    Ibrahim, Nurul 'Izzah
    Saad, Qodriyah Haji Mohd
    Sidik, Tg Mohd Ikhwan Tg Abu Bakar
    Leow, Soon-Sen
    Fairus, Syed
    Mohamed, Isa Naina
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] EFFICACY AND SAFETY OF CREATINE SUPPLEMENTATION IN JUVENILE DERMATOMYOSITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL
    Solis, Marina Yazigi
    Hayashi, Ana Paula
    Artioli, Guilherme Giannini
    Roschel, Hamilton
    Sapienza, Marcelo Tatit
    Otaduy, Maria Concepcion
    De Sa Pinto, Ana Lucia
    Silva, Clovis Artur
    Elias Sallum, Adriana Maluf
    Pereira, Rosa Maria R.
    Gualano, Bruno
    [J]. MUSCLE & NERVE, 2016, 53 (01) : 58 - 66
  • [24] Safety and tolerability of medicinal parasite ova (Trichuris suis) in healthy Japanese volunteers: A randomized, double-blind, placebo-controlled trial
    Hoshina, Tokio
    Sakurai, Tatsuya
    Ichimura, Hidetoshi
    Ishiwata, Kenji
    En, Shitan
    Yamada, Takahiro
    Kwangyole, Lee
    Shimizu, Akihiro
    Hase, Koji
    Kanuka, Hirotaka
    [J]. PARASITOLOGY INTERNATIONAL, 2021, 85
  • [25] Pharmacokinetics and Tolerability of Single Escalating Doses of Gabapentin Enacarbil: A Randomized-Sequence, Double-Blind, Placebo-Controlled Crossover Study in Healthy Volunteers
    Lal, Ritu
    Sukbuntherng, Juthamas
    Luo, Wendy
    Chen, Dan
    Vu, Amanda
    Tovera, James
    Cundy, Kenneth C.
    [J]. CLINICAL THERAPEUTICS, 2009, 31 (08) : 1776 - 1786
  • [26] Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers
    Rocha, Jose-Francisco
    Santos, Ana
    Gama, Helena
    Moser, Paul
    Falcao, Amilcar
    Pressman, Peter
    Wallace Hayes, A.
    Soares-da-Silva, Patricio
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (02) : 391 - 403
  • [27] A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers
    Jansen, Mendel
    Warrington, Steven
    Dishy, Victor
    Ohwada, Shoichi
    Johnson, Lisa
    Brown, Karen
    Ishizuka, Hitoshi
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 661 - 669
  • [28] Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study
    Bata, M. S.
    Al-Ramahi, M.
    Salhab, A. S.
    Gharaibeh, M. N.
    Schwartz, Jill
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08): : 925 - 932
  • [29] Suppression of tics with baclofen: Double-blind, placebo-controlled, crossover clinical trial
    Singer, HS
    Krieger, M
    Wendlandt, JT
    Guiliano, J
    [J]. ANNALS OF NEUROLOGY, 2000, 48 (03) : 544 - 545
  • [30] Human Safety and Pharmacokinetics Study of Orally Administered Icariin: Randomized, Double-Blind, Placebo-Controlled Trial
    Brown, E. Sherwood
    Bice, Collette
    Putnam, William C.
    Leff, Richard
    Kulikova, Alexandra
    Nakamura, Alyson
    Ivleva, Elena I.
    Enkevort, Erin Van
    Holmes, Traci
    Miingi, Nyokabi
    [J]. NATURAL PRODUCT COMMUNICATIONS, 2019, 14 (06)
12345